Stock Updates

How has Novo Nordisk A/S:(NYSE:NVO) performed recently?

Novo Nordisk A/S (NYSE: NVO) is a large market cap stock with a market cap of 107717.59. It is in the Drug Manufacturers – Other industry and sector Healthcare, with a current P/E of 27.03, a forward P/E of 21.75 and EPS of 2.01. At a stock price of 54.23 (-0.07%) it has a dividend yield of 1.77%.

EPS growth for the last five years have been 22.40%, more recently this last year it has grown by 34.30%. The next year growth is going to be about 8.39% and more long-term 11.70% after five years. EPS growth quarter over quarter is -2.20%. Sales growth for the past five years have been 12.20% and sales growth quarter over quarter is 8.00%.

For performance, Novo Nordisk A/S the past week has seen a gain of 6.52%. For the last month performance for Novo Nordisk A/S is -4.17%. While the last quarter is -1.74% and half year, -3.68%. Finally for the year, performance is 0.75%.

The 52-week high for Novo Nordisk A/S, is at -8.53%, and for the 52-week low it comes to a value of 19.54%. The 20-day simple moving average is -0.38% and 0.37% for the 200-day simple moving average.

Volatility for the week is at 1.31%, and for the month it is 1.50%. Novo Nordisk A/S, has a target price of 60.1.

In terms of debt, long term debt/equity is 0, and for total debt/equity Novo Nordisk A/S has 0.01. The gross margin is 84.90%, while operating margin is 43.60%, the profit margin is 31.30%. The current ratio is 1.1 and the quick ratio is 0.8.

Insider ownership is at 26.40%, with instituitional ownership at 10.20%. Novo Nordisk A/S has a payout ratio of 47.50%. With the total shares outstanding coming to 1986.31. The shares float is 1356.68, with the float short at 0.18%, with short ratio coming to 1.79.

In terms of returns, the return on assets see Novo Nordisk A/S, get 40.40%, with its returns on investment at 85.00%. Return on equity is 82.70%. So will the investors see the target price of 60.1, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Peter Clarke

Leave a Comment